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	 2,3‐Dihydroquinazolin‐4(1H)‐one	 derivatives	 (3a‐p)	 were	 synthesized	 in	 excellent	 yields.
These	 compounds	were	screened	 for	 antiproliferative	activity	against	A549	 cells	 and	were
found	 as	 potent	 cytotoxicity.	 Compounds	 A4,	 A8,	 A10	 found	 to	 be	 more	 promising
antiproliferative	 against	 the	 lung	 carcinoma	A549	 cells.	 IC50	 values	 for	 compounds	 A4,	 A8
and	A10	were	found	to	be	8.6,	8.9	and	8.1	μg/L	against	A549	cells,	respectively.	
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1.	Introduction	
	
Various	 quinazolinones	 were	 found	 as	 natural	 products	
and	attracted	a	 vast	 attention	because	of	 their	wide	 range	of	
biological	 activities.	 Previous	 reports	 of	 their	 derivatives	
showed	 significant	 effects	 in	 different	 pharmaceutical	 pro‐
ducts	[1‐3].	Quinazolinone	derivatives	also	reported	as	poten‐
tial	 antimicrobial	 [4],	 antimalarial	 [5],	 antitumor	 [6,7],	 anti‐
depressant	[8],	analgesic	[9],	CNS	stimulant	[10],	tranquilizing	
[11]	and	anticancer	agent	 [12].	Reaction	of	2‐aminobezamide	
and	aromatic	aldehydes	were	widely	used	for	the	synthesis	of	
quinazolinones	derivatives.	This	is	an	efficient	method	for	the	
synthesis	 of	 potentially	 active	 quinazolinone	 derivatives.	
Quinazolinone	moieties	are	significant	for	biological	activities	
in	 healthcare	 and	 medicines.	 In	 addition,	 quinazolinone	
heterocyclic	 is	 also	 utilized	 as	 a	 backbone	 skeleton	 of	 some	
drugs	 such	 as	 cloroqualone,	 afloqualone	 and	 quinethazone	
(Figure	1).	
Therefore	 a	 simple,	 mild,	 and	 versatile	 preparation	
method	 of	 quinazolinones	 in	 one‐pot	 reaction	 is	 still	 highly	
desirable.	 In	continuation	of	our	research	devoted	to	the	new	
methods	 for	 the	 preparation	 of	 heterocyclic	 compounds	 via	
multicomponent	 reactions,	 we	 describe	 the	 synthesis	 of	
quinazolinone	 derivatives	 using	 2‐anthranilamides	 and	
aromatic	 substituted	 aldehydes	 in	 ethanol	 under	 reflux	
condition.		
Several	methods	has	been	used	for	cyclocondensation	of	2‐
anthranilamides	 with	 aldehydes	 in	 the	 presence	 of	 various	
promoting	agents,	such	as	Lewis	acids	CuCl2.2H2O	[13],	Cerium	
(iv)	 sulphates	 tertrahydes	 [14],	 cyanuric	 chlorides	 [15],	
Amberlyst‐15	 [16]	 and	 SnCl2	 [17].	 Reaction	was	 also	 carried	
out	 by	 acids	 catalyzed	 one‐pot	 synthesis	 using	 PTSA	 [18],	
silica‐SO3H	[19],	acetic	acid	[20]	and	also	 in	presence	of	alum	
[21]	montmorillonite	K‐10	[22],	thiamine	hydrochloride	(VB1)	
[23].	 Recently,	 nano‐catalyst	 metal‐CNTs	 [24],	 Wang‐OSO3H	
[25],	 basic	 ionic	 liquid	 [26]	 and	 [bmim]	 HSO4	 [27],	 ceric	
ammonium	nitrate	[28]	were	also	used	in	this	transformation.	
Eventhough	 significant	 improvements	 and	 developments	
using	various	catalysts	have	been	achieved;	this	protocol	lacks	
implementation	 and	 limitations	 such	 as	 the	 use	 of	 excess	 of	
solvent,	 moisture	 sensitive,	 corrosive,	 expensive	 catalysts,	
tedious	 separation	procedures	 for	 recovery	of	 catalysts	 leads	
to	toxic	waste	generation	along	with	a	long	reaction	time,	high	
temperature	and	low	yield	of	the	desired	products.	
318	 Deshmukh	et	al.	/	European	Journal	of	Chemistry	8	(3)	(2017)	317‐320	
	
	
 
	
Figure	1.	Some	example	of	quinazolinone	active	heterocyclic	compounds.
	
 
	
Scheme	1	
	
	
Herein,	 we	 report	 a	 mild	 and	 efficient	 protocol	 for	 the	
synthesis	 of,	 2,3‐dihydroquinazolin‐4(1H)‐one	 derivatives	 in	
presence	ionic	liquid	under	mild	condition	(Scheme	1).	
	
2.	Experimental	
	
2.1.	Instrumentations	
	
1H	 NMR	 spectra	 were	 recorded	 in	 solvent	 DMSO	 using	
Varian	 spectrometer	 instrument	 1H	 (400	 MHz)	 at	 25	 °C	
temperature.	 Chemical	 shifts	 were	 reported	 in	 δ	 ppm	 with	
tetramethylsilane	 as	 an	 internal	 standard	 (TMS,	 δ	 =	 0.0).	
Infrared	 spectra	 were	 recorded	 on	 a	 FT‐IR	 spectrometer	
(Shimadzu	FT‐IR	8300	spectrophotometer)	in	a	range	of	400‐
4000	 cm‐1.	 Mass	 spectra	 were	 recorded	 on	 VG‐7070H	
Micromass.	Melting	points	taken	are	uncorrected.		
	
2.2.	Synthesis	of	the	quinazolinones	derivatives	
	
In	 a	 round	 bottom	 flask	 (10	 mL),	 2‐aminobenzamide	 (1	
mmol)	and	substituted	aldehydes	2a	(1	mmol)	were	added.	To	
it	1‐ethyl‐3‐methylimidazolium	hydrogen	sulphate	(10	mol	%)	
catalysts	was	 added	 in	 ethanol	 (5	mL).	 The	 reaction	mixture	
was	heated	under	reflux	for	appropriate	time.	The	progress	of	
reactions	 was	 monitored	 by	 using	 TLC.	 After	 completion	 of	
reaction	 the	 product	 obtained	was	 poured	 onto	 crushed	 ice.	
The	 solid	 obtained	 was	 filtered	 and	 recrystallized	 in	 hot	
ethanol	to	afford	the	pure	product.	
2‐(4‐Fluorophenyl)‐2,3‐dihydroquinazolin‐4(1H)‐one	 (3a):	
Color:	White.	M.p.:	203‐205	°C.	FT‐IR	(KBr,	ν,	cm‐1):	2915	(C‐
H),	1625	(C=C).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	5.77	(s,	
1H,	N‐H),	6.69	(d,	2H,	Ar‐H),	7.19	(s,	1H,	Ar‐H),	7.27	(t,	1H,	C‐
H),	7.30	(dd,	4H,	Ar‐H),	7.55	(d,	1H,	Ar‐H),	8.56	(s,	1H,	N‐H).	13C	
NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 66.42,	 115.0,	 115.51,	
115.53,	118.0,	126.99,	130.50,	132.87,	139.25,	149.07,	162.06,	
163.00.	EI‐MS	(m/z):	243	[M+1]+.	
2‐(3‐Nitrophenyl)‐2,3‐dihydroquinazolin‐4(1H)‐one	 (3o):	
Color:	White.	M.p.:	205‐206	°C.	FT‐IR	(KBr,	ν,	cm‐1):	2914	(C‐
H),	 1610	 (C=C),	 1456	 (C‐Cl).	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	
ppm):	5.73	 (s,	 1H,	N‐H),	6.7	 (d,	2H,	Ar‐H),	7.17	 (s,	1H,	Ar‐H),	
7.22	(t,	1H,	C‐H),	7.4	(dd,	4H,	Ar‐H),	7.6	(d,	1H,	Ar‐H),	8.39	(s,	
1H,	N‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	66.76,	78.11	
79.28,	114.37,	118.11,	126.98,	128.14,	132.54,	133.74,	140.34,	
146.57,	163.32.	EI‐MS	(m/z):	269	[M+1]+.	
	
	
2.3.	Cell	culture	conditions	
	
A	 lung	 carcinoma	 cell	 A549	 were	 maintained	 in	 RPMI‐
1640	 containing	 10	 %	 v/v	 FBS	 (Life	 technologies	 Inc.	 USA).	
The	 cells	 sub‐cultured	 and	 incubated	 at	 37	 °C	 and	 5%	 CO2	
incubator.	For	all	experiments,	the	cells	were	freshly	grown	by	
diluting	 the	 stock	 solution	 with	 D‐phosphate‐buffered	 saline	
(pH	=	7.2)	(Hi	Media,	India).	
	
2.4.	Determination	of	cell	viability	and	IC50	
	
The	 antiproliferative	 effect	 of	 compounds	 on	 Lung	 carci‐
noma	 cells	 was	 evaluated	 by	 Vybrant	MTT	 Cell	 Proliferation	
Assay	 Kit	 (Life	 technologies	 Inc.	 USA).	 The	 procedure	 was	
adopted	 described	 previously	 [29].	 Briefly,	 the	 cells	 were	
plated	at	~1×104	cells	in	each	well	of	96	well	plate	in	100	μL	of	
RPMI‐1640	 medium.	 All	 the	 compounds	 (0,	 5,	 10,	 25,	 50	
µg/mL)	 were	 added	 to	 each	 well	 separately.	 The	 standard	
reference	 drug	 Doxorubicin	 (10	 uM)	was	 used.	 Cell	 viability	
was	determined	after	24	hrs	incubation	in	CO2	incubator	at	37	
°C.	 MTT	 (5	 mg/mL	 in	 PBS)	 was	 added	 to	 each	 well	 and	
incubated	for	4	hrs.	The	absorbance	was	recorded	at	490	nm	
using	a	96	well	Multiscan	Ascent	(Thermo	Inc.USA).	The	IC	50	
was	calculated	by	using	formula	
	
2.5.	Statistical	analysis	
	
Dose‐response	 curves	 were	 plotted	 to	 determine	 IC50	
values	 using	 the	 GraphPad	 Prism.	 p‐values	<	 0.05	 were	
considered	significant.	
	
3.	Results	and	discussion	
	
Initially,	 we	 tried	 anthranilamide	 (1	 mmol)	 and	 4‐NO2	
benzaldehyde	 (2a)	 (1	mmol)	 as	 the	model	 reaction	 by	 using	
copper	 silicates	 catalyst	 in	 acetonitrile	 at	 room	 temperature;	
obtained	 product	 formation	 takes	 place	 in	 very	 low	 yield	
(Table	1,	Entry	1).	To	 improve	the	product	yield	 the	reaction	
condition	 like	 sonification	 and	 reflux	 condition	 of	 reaction	
were	 changed	 and	 the	 yield	 was	 increased	 up	 to	 80‐82	 %	
(Table	1,	Entry	2‐3).	
The	 modified	 conditions	 for	 reactions	 along	 with	 the	
alteration	in	the	temperature	enhance	the	product	yield	(Table	
1,	Entry	4‐6).		
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Table	1.	Optimization	of	reaction	conditions	using	various	solvent	and	catalyst.	
Entry	 Solvent	 Catalyst	 Temp.	(°C)	 Yield	(%)		
1	 Acetonitrile	 Copper	silicate		 RT	 60
2	 Acetonitrile	 Copper	silicate		 Sonication	 80
3	 Acetonitrile	 Copper	silicate		 78		 82
4	 Ethanol	 Copper	silicate		 RT	 70
5	 Ethanol	 Copper	silicate		 Sonication	 84	
6	 Ethanol	 Copper	silicate		 78	 86	
7	 Acetonitrile	 Camphor	sulphonic	acid RT	 68
8	 Acetonitrile	 Camphor	sulphonic	acid		 Sonication	 72	
9	 Acetonitrile	 Camphor	sulphonic	acid		 78		 74	
10	 Ethanol	 Camphor	sulphonic	acid	 RT	 70
11	 Ethanol	 Camphor	sulphonic	acid	 Sonication	 74
12	 Ethanol	 Camphor	sulphonic	acid	 78	 77
13	 Acetonitrile	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate RT	 74
14	 Acetonitrile	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate Sonication	 81
15	 Acetonitrile	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate	 78		 82	
16	 Ethanol	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate RT	 84
17	 Ethanol	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate	 Sonication	 90	
18	 Ethanol	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate	 78	 94	
19	 Ethanol	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate,	15	%	 78	 94	
20	 Ethanol	 1‐Ethyl‐3‐methylimidazolium	hydrogen	sulphate,	20	% 78	 94
	
	
Table	2.	Reaction	of	2‐anthranilamide	and	various	aldehydes	for	the	preparation	of	2,3‐dihydroquinazolinone.	
	
Entry	 Aldehydes	(2)	 R1	 R2 R3 2,3‐Dihydroquinazolinone	(3a‐p) Code	 Time	(min)	 Yield	a	(%)
1	 4‐Fluorobenzaldehyde	 H	 H	 ‐F	 3a	 A1	 142	 93	
2	 3‐Nitrobenzaldehyde	 H	 NO2						 H	 3b	 A2	 155	 89	
3	 4‐Hydroxy‐3‐methoxybenzaldehyde	 H	 OCH3	 OH	 3c	 Â3	 163	 84	
4	 1‐Naphthaldehyde	 H	 H H 3d A4 161	 87
5	 4‐Methylbenzaldehyde	 H	 H	 Me	 3e	 A5	 154	 89	
6	 4‐Bromobenzaldehyde	 H	 H Br 3f A6 130	 91
7	 4‐Hydroxybenzaldehyde	 H	 H OH 3g A7 150	 87
8	 3‐Hydroxybenzaldehyde	 H	 OH H 3h A8 167	 81
9	 2‐Nitrobenzaldehyde	 NO2	 H H 3i A9 168	 86
10	 2,4‐Dichlorobenzaldehyde	 Cl	 Cl H 3j A10 150	 89
11	 3‐Bromobenzaldehyde	 H	 Br H 3k A11 160	 84
12	 2,3‐Dichlorobenzaldehyde	 Cl	 Cl	 H	 3l	 A12	 150		 87	
13	 Benzaldehyde	 H	 H H 3m A13 180	 80
14	 4‐Nitrobenzaldehyde	 H	 H	 NO2	 3n	 A14	 140	 94	
15	 3‐Chlorobenzaldehyde	 H	 NO2	 H	 3o	 A15	 120	 93	
16	 2,4,6‐Trimethoxybenzaldehyde	 OCH3	 OCH3	 OCH3	 3p	 A16	 170	 78	
a	Isolated	yield.	
	
	
The	use	of	camphor	sulphonic	acids	in	acetonitrile	solvents	
with	different	reaction	conditions	has	been	carried	out	(Table	
1,	Entry	7‐9).	It	indicates,	there	is	a	scope	to	increase	yield	of	
product	 by	 changing	 the	 solvent	 as	 ethanol	 with	 different	
reaction	 conditions	 (Table	1,	Entry	9‐12).	Our	 interest	 in	 the	
area	of	developing	green	and	sustainable	method,	has	 forced	
us	to	investigate	an	alternate	milder	method	for	the	synthesis	
of	2,3‐dihydroquinazolin‐4(1H)‐one	derivatives	(Table	2).		
Herein,	 we	 report	 a	 green	 protocol	 for	 the	 synthesis	 of	
synthesis	 of	 2,3‐dihydroquinazolin‐4(1H)‐one	 derivatives	
under	 reflux	 conditions	 by	 using	 cheap	 and	 readily	 available	
ionic	 liquids	 as	 catalyst	 under	 milder	 reaction	 conditions	
(Table	 1,	 Entry	 13).	 To	 change	 the	 reaction	 conditions	 with	
acetonitrile	 at	 sonifaction	 and	 reflux	 condition,	 good	 yield	 of	
product	 were	 obtained	 (Table	 1,	 Entry	 14‐15).	 The	 reaction	
solvent	 has	 been	 replaced	 to	 ethanol	 at	 room	 temperature	
reaction	 conditions	 gave	 the	 good	 yield	 of	 product	 (Table	 1,	
Entry	16‐17).	The	best	result	was	obtained	at	reflux	conditions	
(Table	 1,	 Entry	 18).	 Increasing	 the	 amount	 of	 catalyst	 (15	
mol%)	 did	 not	 improve	 the	 yield	 (Table	 1,	 Entry	 19‐20).	
Whereas	 in	 the	 absence	 of	 catalyst	 less	 amount	 product	was	
obtained.	
	
3.1.	Biological	activity	
	
3.1.1.	Determination	of	IC50	
	
A	lung	carcinoma	cells	(A549)	were	treated	with	screening	
compounds	and	antiproliferative	effect	was	evaluated	by	MTT	
assay.	A	dose	dependant,	decreases	the	growth	of	cancer	cells	
with	increasing	concentration	of	the	compounds.	IC50	value	of	
compounds	in	A549	cells	are	shown	in	Figure	2.	
The	results	obtained	by	MTT	assay	at	490	nm	by	addition	
of	compounds	to	cancer	cells	and	incubated	for	24	h	at	37	°C	in	
CO2	incubator	(5	%	CO2)	where	a)	A2,	A3,	A4,	A5	compounds,	
b)	A6,	A7,	A8,	A9	 compounds,	c)	A10,	A11,	A12,	A13	and	d)	
A14,	 A15,	 A16,	 Dox.	 The	 IC50	 calculated	 by	 using	 the	
GraphPad	Prism	software.		
The	MTT	assay	was	used	to	evaluates	the	antiproliferative	
action	of	compounds	at	different	concentrations	(0,	5,	10,	25,	
50	 μg/L)	 on	 A549	 cells.	 After	 24	 h	 exposure	 to	 compounds;	
approximately	 2‐fold	 decrease	 in	 cell	 survival	 between	 the	
control	 (0	 μg/L)	 and	 compounds	 treated	 cells	 has	 been	
reported	(Figure		2).		
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(a)	
	 	(b)	
	
(c)	
	
(d)	
	
Figure	2.	Dose	dependent	effect	of	quinazolinones	derivatives	on	the	growth	of	cancer	cells	(A	549)	where	a)	A2,	A3,	A4,	A5	compounds,	b)	A6,	A7,	A8, A9
compounds,	c)	A10,	A11,	A12,	A13	and	d)	A14,	A15,	A16,	Dox.	
	
	
Compound	A4,	A8,	A10	were	found	to	be	more	promising	
antiproliferative	 against	 the	 lung	 carcinoma	 A549	 cells.	 The	
IC50	values	 for	compounds	A4,	A8	and	A10	were	 found	to	be	
8.133,	 9.056	 and	 9.169	 μg/L	 in	 A549	 cells,	 respectively.	
Doxorobucin	was	 used	 as	 a	 standard	 reference	 drug	 for	 this	
assay.		
	
4.	Conclusion	
	
In	 conclusion,	 we	 have	 successfully	 developed	 a	 greener	
protocol	 for	 the	 synthesis	 of	 2,	 3‐dihydroquina‐zolin‐4(1H)‐
ones	using	1‐Ethyl‐3‐Methylimidazolium	hydrogen	sulphate	as	
an	 expeditious	 and	 reusable	 catalyst	 at	 reflux	 conditions.	 A	
wide	range	of	products	bearing	different	functionalized	groups	
are	 easily	 isolated.	 The	 method	 offers	 several	 advantages	
including,	 high	 yield	 of	 products,	 short	 reaction	 time,	
recyclability	 of	 catalyst,	 and	 the	 fact	 that	 the	 crude	 is	
recrystallized	from	methanol	to	give	the	pure	product	without	
further	 column	 purification.	 Compounds	 showed	 the	
inhibitory	 effect	 on	 the	 growth	 of	 cancer	 cells	 (A549).	
Compounds	A4,	A8	and	A10	were	found	to	be	more	promising	
antiproliferative	against	the	lung	carcinoma	A549	cells.	
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